Mantle Cell Lymphoma of Mucosa‐Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
Open Access
- 10 December 2019
- journal article
- research article
- Published by Wiley in HemaSphere
- Vol. 4 (1), e302
- https://doi.org/10.1097/hs9.0000000000000302
Abstract
While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6–182), 5-year progression-free survival (PFS) was 45% (95% CI: 35–54) and 5-year overall survival (OS) was 71% (95% CI: 62–79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.This publication has 21 references indexed in Scilit:
- A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcomeBlood, 2018
- Mantle Cell Lymphoma in the Thyroid: A Rare PresentationCase Reports in Pathology, 2017
- Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studiesBritish Journal of Haematology, 2017
- Clinical Impact of the 2016 Update to the WHO Lymphoma ClassificationCurrent Treatment Options in Oncology, 2017
- Primary bone mantle cell lymphomas with multiple vertebral compression fractures: A case reportOncology Letters, 2017
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical FeaturesCancer Research, 2012
- Improvement of Overall Survival in Advanced Stage Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood, 2008
- Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic StudyThe American Journal of Surgical Pathology, 2006
- Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtypeLeukemia, 2001